person · Reporting owner

INGRAM ROBERT ALEXANDER

Disclosed activity across 9 companies

Tapewire entity: 16884
SEC CIK: 0001219890

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315	Director	February 28, 2023	March 02, 2023
Bausch Health Companies Inc.VRX · Entity 4363	Director	March 31, 2017	April 04, 2017
G1 Therapeutics, Inc.GTHX · Entity 87413	10% owner	May 30, 2018	June 01, 2018
LOWES COMPANIES INCLOW · Entity 2896	Director	March 31, 2011	April 04, 2011
Novan, Inc.NOVN · Entity 111882	Director	July 28, 2020	July 30, 2020
PhaseBio Pharmaceuticals IncPHAS · Entity 113305	10% owner	October 22, 2018	October 24, 2018
WOLFSPEED, INC.CREE · Entity 619	Director	October 17, 2018	October 18, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOCRYST PHARMACEUTICALS INC

Report date February 28, 2023 · Filed March 02, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	100,198	Reported balance After 2023-02-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-02-28 · Grant · Acquired 2,259 · Balance 100,198 F1: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000.

Bausch Health Companies Inc.

Report date March 31, 2017 · Filed April 04, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, no par valueSEC Table I · non-derivative	Direct	92,046	Reported balance After 2017-03-31 transaction · row 1 1 source row Row 1 · 2017-03-31 · Grant · Acquired 2,120 · Balance 92,046 F1: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

G1 Therapeutics, Inc.

Report date May 30, 2018 · Filed June 01, 2018

Jointly reported with Thorp Clay, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Partners IV SBIC, LP, Crumpler John, LEE KENNETH B JR, Reed Douglas MD

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,279,421	Reported balance After 2018-05-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-05-30 · Sale · Disposed 758,290 · Balance 3,279,421 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,237,711	Reported balance After 2018-05-30 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-05-30 · Sale · Disposed 41,710 · Balance 3,237,711 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC. F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

Filing footnotes · ownership attribution and instrument terms

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.

F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

LOWES COMPANIES INC

Report date March 31, 2011 · Filed April 04, 2011

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	32,429.879	Reported balance After 2011-03-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2011-03-31 · Grant · Acquired 709.421 · Balance 32,429.879 F1: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program. F2: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's. F3: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Novan, Inc.

Report date July 28, 2020 · Filed July 30, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2030-07-27	Direct	20,000	Reported balance After 2020-07-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-07-28 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests in four equal quarterly installments, with the first installment vesting on October 28, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in four equal quarterly installments, with the first installment vesting on October 28, 2020.

PhaseBio Pharmaceuticals Inc

Report date October 22, 2018 · Filed October 24, 2018

Jointly reported with Hatteras Venture Advisors III, LLC, Hatteras Ventures Partners III LP, Hatteras Venture Affiliates III Lp, Hatteras Venture Partners I, LP, Catalysta Ventures, LLC, Venture Capital Multiplier Fund, LEE KENNETH B JR, Reed Douglas MD, Crumpler John

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Hatteras Venture Partners I, LP	52,690	Reported balance After 2018-10-22 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-10-22 · Conversion · Acquired 52,690 · Balance 52,690 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Common StockSEC Table I · non-derivative	IndirectBy Hatteras Venture Partners III, LP	1,820,933	Last balance in matching sequence After 2018-10-22 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2018-10-22 · Conversion · Acquired 1,683,420 · Balance 1,683,420 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Row 3 · 2018-10-22 · Purchase · Acquired 137,513 · Balance 1,820,933 F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Common StockSEC Table I · non-derivative	IndirectBy Hatteras Venture Affiliates III, LP	163,099	Last balance in matching sequence After 2018-10-22 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 4 · 2018-10-22 · Conversion · Acquired 150,612 · Balance 150,612 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Row 5 · 2018-10-22 · Purchase · Acquired 12,487 · Balance 163,099 F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Common StockSEC Table I · non-derivative	IndirectBy Catalysta Ventures, LLC	4,846	Reported balance After 2018-10-22 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2018-10-22 · Conversion · Acquired 4,846 · Balance 4,846 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Common StockSEC Table I · non-derivative	IndirectBy Venture Capital Multiplier Fund	416,481	Last balance in matching sequence After 2018-10-22 transaction · row 8 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 7 · 2018-10-22 · Conversion · Acquired 266,481 · Balance 266,481 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Row 8 · 2018-10-22 · Purchase · Acquired 150,000 · Balance 416,481 F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Warrants to Purchase Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12	IndirectBy Hatteras Venture Partners III, LP	0	Reported balance After 2018-10-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-10-22 · Other · Disposed 19,061 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	1,045,222	Reported balance After 2018-10-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-10-22 · Other · Acquired 19,061 · Balance 1,045,222 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	1,044,764	Reported balance After 2018-10-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-10-22 · Sale · Disposed 458 · Balance 1,044,764 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	0	Reported balance After 2018-10-22 transaction · row 30 Instrument identity requires review; Table II rows are not merged. 1 source row Row 30 · 2018-10-22 · Conversion · Disposed 1,044,764 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Warrants to Purchase Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12	IndirectBy Hatteras Venture Affiliates III, LP	0	Reported balance After 2018-10-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-10-22 · Other · Disposed 1,731 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	94,916	Reported balance After 2018-10-22 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2018-10-22 · Other · Acquired 1,731 · Balance 94,916 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	94,874	Reported balance After 2018-10-22 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2018-10-22 · Sale · Disposed 42 · Balance 94,874 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	0	Reported balance After 2018-10-22 transaction · row 31 Instrument identity requires review; Table II rows are not merged. 1 source row Row 31 · 2018-10-22 · Conversion · Disposed 94,874 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12	IndirectBy Hatteras Venture Partners III, LP	0	Reported balance After 2018-10-22 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2018-10-22 · Other · Disposed 47,458 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	150,459	Reported balance After 2018-10-22 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2018-10-22 · Other · Acquired 47,458 · Balance 150,459 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	149,320	Reported balance After 2018-10-22 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2018-10-22 · Sale · Disposed 1,139 · Balance 149,320 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	0	Reported balance After 2018-10-22 transaction · row 32 Instrument identity requires review; Table II rows are not merged. 1 source row Row 32 · 2018-10-22 · Conversion · Disposed 149,320 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12	IndirectBy Hatteras Venture Affiliates III, LP	0	Reported balance After 2018-10-22 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2018-10-22 · Other · Disposed 4,309 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	13,662	Reported balance After 2018-10-22 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2018-10-22 · Other · Acquired 4,309 · Balance 13,662 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	13,558	Reported balance After 2018-10-22 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2018-10-22 · Sale · Disposed 104 · Balance 13,558 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	0	Reported balance After 2018-10-22 transaction · row 33 Instrument identity requires review; Table II rows are not merged. 1 source row Row 33 · 2018-10-22 · Conversion · Disposed 13,558 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12	IndirectBy Venture Capital Multiplier Fund	0	Reported balance After 2018-10-22 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2018-10-22 · Other · Disposed 41,414 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Venture Capital Multiplier Fund	41,414	Reported balance After 2018-10-22 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2018-10-22 · Other · Acquired 41,414 · Balance 41,414 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Venture Capital Multiplier Fund	40,420	Reported balance After 2018-10-22 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2018-10-22 · Sale · Disposed 994 · Balance 40,420 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Venture Capital Multiplier Fund	0	Reported balance After 2018-10-22 transaction · row 34 Instrument identity requires review; Table II rows are not merged. 1 source row Row 34 · 2018-10-22 · Conversion · Disposed 40,420 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series 1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners I, LP	0	Reported balance After 2018-10-22 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2018-10-22 · Conversion · Disposed 52,690 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series 1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	0	Reported balance After 2018-10-22 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2018-10-22 · Conversion · Disposed 42,530 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series 1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	0	Reported balance After 2018-10-22 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2018-10-22 · Conversion · Disposed 3,862 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series 1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Catalysta Ventures, LLC	0	Reported balance After 2018-10-22 transaction · row 27 Instrument identity requires review; Table II rows are not merged. 1 source row Row 27 · 2018-10-22 · Conversion · Disposed 4,846 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series AA Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	0	Reported balance After 2018-10-22 transaction · row 28 Instrument identity requires review; Table II rows are not merged. 1 source row Row 28 · 2018-10-22 · Conversion · Disposed 174,699 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series AA Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	0	Reported balance After 2018-10-22 transaction · row 29 Instrument identity requires review; Table II rows are not merged. 1 source row Row 29 · 2018-10-22 · Conversion · Disposed 13,609 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Partners III, LP	0	Reported balance After 2018-10-22 transaction · row 35 Instrument identity requires review; Table II rows are not merged. 1 source row Row 35 · 2018-10-22 · Conversion · Disposed 272,107 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectBy Hatteras Venture Affiliates III, LP	0	Reported balance After 2018-10-22 transaction · row 36 Instrument identity requires review; Table II rows are not merged. 1 source row Row 36 · 2018-10-22 · Conversion · Disposed 24,709 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectBy Venture Capital Multiplier Fund	0	Reported balance After 2018-10-22 transaction · row 37 Instrument identity requires review; Table II rows are not merged. 1 source row Row 37 · 2018-10-22 · Conversion · Disposed 226,061 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

WOLFSPEED, INC.

Report date October 17, 2018 · Filed October 18, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	77,710	Reported balance After 2018-10-17 transaction · row 1 1 source row Row 1 · 2018-10-17 · Grant · Acquired 760 · Balance 77,710 F1: Represents shares of Common Stock credited to the Reporting Person's 2018 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Common Stock credited to the Reporting Person's 2018 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Black Diamond Therapeutics, Inc.

Report date December 16, 2022 · Filed December 20, 2022

Section 16 reporting ended · disclosed 2022-12-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	42,854	Reported balance After 2022-12-16 transaction · row 1 1 source row Row 1 · 2022-12-16 · Grant · Acquired 9,375 · Balance 42,854 F1: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022.

Clearside Biomedical, Inc.

Report date January 17, 2017 · Filed January 19, 2017

Jointly reported with Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Partners IV SBIC, LP, Crumpler John, LEE KENNETH B JR, Reed Douglas MD, Thorp Clay

Section 16 reporting ended · disclosed 2017-01-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,060,514	Last balance in matching sequence After 2017-01-19 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2017-01-17 · Sale · Disposed 9,806 · Balance 2,080,364 F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 2 · 2017-01-18 · Sale · Disposed 12,258 · Balance 2,068,106 F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 3 · 2017-01-19 · Sale · Disposed 7,592 · Balance 2,060,514 F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 28, 2023 Filed Mar 2, 2023 21:41 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	2,259	$8.85	$19,992.15	Disclosure SEC source: 0001127602-23-008391 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,198 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000. Read SEC document
December 16, 2022 Filed Dec 20, 2022 02:14 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	9,375	$1.50	$14,062.50	Disclosure SEC source: 0001415889-22-012795 · form4-12202022_021217.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · FORMER DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,854 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022. Read SEC document
November 30, 2022 Filed Dec 2, 2022 23:24 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,497	$13.36	$19,999.92	Disclosure SEC source: 0001127602-22-026823 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,939 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000. Read SEC document
September 16, 2022 Filed Sep 19, 2022 21:08 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	6,584	$2.62	$17,250.08	Disclosure SEC source: 0001415889-22-009771 · form4-09192022_020900.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,479 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 15, 2022. Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:31 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,438	$13.90	$19,988.20	Disclosure SEC source: 0001127602-22-022009 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,442 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000. Read SEC document
June 17, 2022 Filed Jun 17, 2022 20:25 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	8,498	$2.03	$17,250.94	Disclosure SEC source: 0001415889-22-006739 · form4-06172022_010601.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,895 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022. Read SEC document
June 10, 2022 Filed Jun 13, 2022 23:06 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001415889-22-006518 · form4-06132022_040607.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:50 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	30,022	$0.00 Strike: $10.79	$0.00	Disclosure SEC source: 0001127602-22-017165 · form4.xml · derivative · entry 2 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:50 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	12,866	$0.00	$0.00	Disclosure SEC source: 0001127602-22-017165 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,004 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document
May 31, 2022 Filed Jun 2, 2022 20:34 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	2,078	$9.31	$19,346.18	Disclosure SEC source: 0001127602-22-016390 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,138 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000, prorated to $19,347.83 based on the increase in the annual retainer fee effective April 18, 2022. Read SEC document
March 18, 2022 Filed Mar 18, 2022 20:05 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	5,795	$3.02	$17,500.90	Disclosure SEC source: 0001415889-22-003184 · form4-03182022_040302.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,397 F1 · kind: These shares were issued in accordance with the Issuer's Second Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 17, 2022. Read SEC document
February 28, 2022 Filed Mar 2, 2022 21:40 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,128	$16.61	$18,736.08	Disclosure SEC source: 0001127602-22-007725 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,060 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
December 17, 2021 Filed Dec 17, 2021 21:12 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	3,296	$5.31	$17,501.76	Disclosure SEC source: 0001415889-21-006070 · form4-12172021_011225.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,602 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 16, 2021. Read SEC document
November 30, 2021 Filed Dec 2, 2021 21:08 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,554	$12.06	$18,741.24	Disclosure SEC source: 0001127602-21-030043 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,932 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
September 17, 2021 Filed Sep 23, 2021 21:33 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	1,869	$9.90	$18,503.10	Disclosure SEC source: 0001415889-21-004540 · form4-09232021_020923.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,306 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 16, 2021. Read SEC document
August 31, 2021 Filed Sep 2, 2021 20:33 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,177	$15.92	$18,737.84	Disclosure SEC source: 0001127602-21-024776 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,378 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
June 18, 2021 Filed Jun 22, 2021 22:13 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $12.55	$0.00	Disclosure SEC source: 0001104659-21-084242 · tm2120371-6_4seq1.xml · derivative · entry 2 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F3 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 18, 2021 Filed Jun 22, 2021 22:13 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	1,255	$12.95	$16,252.25	Disclosure SEC source: 0001104659-21-084242 · tm2120371-6_4seq1.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,437 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 17, 2021. Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:27 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,188	$15.77	$18,734.76	Disclosure SEC source: 0001127602-21-018501 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,201 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
May 25, 2021 Filed May 27, 2021 20:28 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	40,000	$0.00 Strike: $13.28	$0.00	Disclosure SEC source: 0001127602-21-018181 · form4.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document
March 18, 2021 Filed Mar 23, 2021 00:19 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	677	$24.01	$16,254.77	Disclosure SEC source: 0000899243-21-012953 · doc4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,182 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price of reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 18, 2021. Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:55 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,739	$10.78	$18,746.42	Disclosure SEC source: 0001127602-21-008766 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,013 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
December 15, 2020 Filed Dec 17, 2020 00:42 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantCommon Stock	505	$34.29	$17,316.45	Disclosure SEC source: 0000899243-20-034190 · doc4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,505 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price of reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 14, 2020. Read SEC document
November 30, 2020 Filed Dec 2, 2020 21:14 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	3,669	$5.11	$18,748.59	Disclosure SEC source: 0001127602-20-030285 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,274 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
September 30, 2020 Filed Oct 1, 2020 20:06 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	PurchaseCommon Stock	5,000	$30.46	$152,285.00	Disclosure SEC source: 0000899243-20-026660 · doc4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.33 to $30.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
September 25, 2020 Filed Sep 29, 2020 12:21 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	GrantStock Option (Right to Buy) · Derivative	29,842	$0.00 Strike: $29.65	$0.00	Disclosure SEC source: 0000899243-20-026445 · doc4.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,842 Underlying: Common Stock · 29,842 shares Expires 2030-09-25 F1 · derivative.exercise_date: This option shall vest and become exercisable in thirty-six (36) equal monthly installments following the Grant Date. Read SEC document
August 31, 2020 Filed Sep 2, 2020 20:33 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	4,518	$4.15	$18,749.70	Disclosure SEC source: 0001127602-20-024637 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,605 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
July 28, 2020 Filed Jul 30, 2020 21:11 UTC	Novan, Inc. NOVN · Entity 111882	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.78	$0.00	Disclosure SEC source: 0001467154-20-000116 · wf-form4_159615787147428.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-27 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on October 28, 2020. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:16 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	4,171	$4.50	$18,748.65	Disclosure SEC source: 0001127602-20-018704 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,087 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
May 12, 2020 Filed May 14, 2020 20:27 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	40,000	$0.00 Strike: $5.41	$0.00	Disclosure SEC source: 0001127602-20-016571 · form4.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document
March 01, 2020 Filed Mar 3, 2020 21:47 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	6,250	$3.00	$18,750.00	Disclosure SEC source: 0001127602-20-009058 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,916 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
December 01, 2019 Filed Dec 3, 2019 22:09 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	6,578	$2.85	$18,747.30	Disclosure SEC source: 0001127602-19-034162 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,666 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
November 18, 2019 Filed Nov 18, 2019 21:12 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	PurchaseCommon Stock	20,000	$1.45	$29,000.00	Disclosure SEC source: 0001127602-19-033025 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,088 Read SEC document
September 01, 2019 Filed Sep 4, 2019 20:08 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	6,270	$2.99	$18,747.30	Disclosure SEC source: 0001127602-19-027858 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,088 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document
July 31, 2019 Filed Aug 2, 2019 16:16 UTC	Novan, Inc. NOVN · Entity 111882	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $2.63	$0.00	Disclosure SEC source: 0001467154-19-000058 · wf-form4_156477694767026.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-07-30 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on October 31, 2019. Read SEC document
May 29, 2019 Filed May 31, 2019 20:21 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	30,000	$0.00 Strike: $2.91	$0.00	Disclosure SEC source: 0001127602-19-020312 · form4.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document
May 22, 2019 Filed May 23, 2019 08:31 UTC	Novan, Inc. NOVN · Entity 111882	PurchaseCommon Stock	50,000	$2.21	$110,500.00	Disclosure SEC source: 0001467154-19-000039 · wf-form4_155861465869269.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,777 F1 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.31, inclusive. The reporting person undertakes to provide to Novan, Inc., any security holder of Novan, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries D Preferred Stock · Derivative	226,061	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 37 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 0 Underlying: Common Stock · 226,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries D Preferred Stock · Derivative	24,709	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 36 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 24,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries D Preferred Stock · Derivative	272,107	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 35 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 272,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries C-1 Preferred Stock · Derivative	40,420	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 34 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 0 Underlying: Common Stock · 40,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries C-1 Preferred Stock · Derivative	13,558	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 33 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 13,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries C-1 Preferred Stock · Derivative	149,320	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 32 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 149,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries B Preferred Stock · Derivative	94,874	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 31 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 94,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries B Preferred Stock · Derivative	1,044,764	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 30 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 1,044,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries AA Preferred Stock · Derivative	13,609	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 29 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 13,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries AA Preferred Stock · Derivative	174,699	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 28 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 174,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries 1 Preferred Stock · Derivative	4,846	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 27 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Catalysta Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 4,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries 1 Preferred Stock · Derivative	3,862	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 26 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 3,862 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:18 UTC	PhaseBio Pharmaceuticals Inc PHAS · Entity 113305	ConversionSeries 1 Preferred Stock · Derivative	42,530	$0.00	$0.00	Disclosure SEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 25 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 42,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.